Published in final edited form as:

J Neurol Neurosurg Psychiatry. 2014 December 1; 85(12): 1359–1365. doi:10.1136/jnnp-2013-306314.

Two recurrent mutations are associated with GNE myopathy in the North of Britain

Amina Chaouch^{#1}, Kathryn M Brennan^{#1,2}, Judith Hudson¹, Cheryl Longman³, Jon McConville⁴, Patrick J Morrisson⁴, Maria E Farrugia², Richard Petty², Willie Stewart², Fiona Norwood⁵, Rita Horvath¹, Patrick F Chinnery¹, Donald Costigan⁶, John Winer⁷, Tuomo Polvikoski¹, Estelle Healey⁸, Anna Sarkozy¹, Michela Guglieri¹, Teresinha Evangelista¹, Oksana Pogoryelova¹, Michelle Eagle¹, Kate Bushby¹, Volker Straub¹, and Hanns Lochmüller¹

¹Institute of Genetic Medicine, MRC Centre for Neuromuscular Disease, Newcastle University, Newcastle upon Tyne, UK ²Institute of Neurological Sciences, Glasgow, UK ³West of Scotland Regional Genetics Service, Southern General Hospital, Glasgow, UK ⁴Belfast City Hospital, Belfast, UK ⁵Department of Neurology, King's College Hospital, London, UK ⁶National Institute for Neurology and Neurosurgery, Beaumont Hospital, Dublin, Ireland ⁷Birmingham Muscle and Nerve Centre, Queen Elizabeth, Hospital, Birmingham, UK ⁸Institute of Pathology, Royal Victoria Hospital, Belfast, UK

These authors contributed equally to this work.

Abstract

GNE myopathy is a rare recessive myopathy associated with inclusion bodies on muscle biopsy. The clinical phenotype associated with mutations in the GNE gene is distal muscle weakness and wasting while the quadriceps muscle is preserved. Most of the current information on GNE myopathy has been obtained through studies of Jewish and Japanese patient cohorts carrying founder mutations in the GNE gene. However, little is known about GNE myopathy in Europe where the prevalence is thought to be very low. We report the clinical, pathological, and genetic characteristics of GNE myopathy in Britain and for the first time highlight two common mutations in the Northern part of the United Kingdom as well as a broader spectrum of clinical phenotypes, including asymmetry of weakness at disease onset and slow disease progression with preserved ambulation over several decades. We also propose that the prevalence of GNE myopathy may be underestimated due to the frequent absence of rimmed vacuoles in the muscle biopsy.

Correspondence to: Professor Hanns Lochmüller, Institute of Genetic Medicine, International Centre for Life, Newcastle University, Newcastle upon Tyne. NE1 3BZ, UK, hanns.lochmuller@ncl.ac.uk.

Web-based resources:

www.ons.gov.uk, www.gro-scotland.gov.uk

www.nusra.gov.uk (2011 census)

www.interactive-biosoftware.com/

http://www.dmd.nl/nmdb2/home.php?select_db=GNE

<http://www.clinicaltrials.gov/ct2/show/NCT01634750?term=GNE+myopathy&rank=2>.

Introduction

GNE myopathy is a rare inherited form of distal myopathy associated with inclusion bodies on muscle biopsy. In contrast to other forms of inclusion myopathies^{2–4}, it is recessive in inheritance^{5, 6}. The phenotypic descriptions of GNE myopathy include hereditary inclusion myopathy (hIBM), quadriceps sparing myopathy, distal myopathy with rimmed vacuoles, and more rarely myopathy with facial diplegia or proximal weakness. Historical differences in nomenclature and classification may have led to an underestimation of the disease prevalence⁷. Recently, the term GNE myopathy has been coined to encompass all these phenotypic subgroups.

The diagnostic criteria of GNE myopathy include myopathy of early distal weakness, onset in early adulthood, mild or normal serum creatine kinase (CK) levels, rimmed vacuoles and detection of 14–18nm filamentous inclusions^{7, 8}. Inflammatory infiltrates are rarely seen in GNE myopathy in contrast to the sporadic form of inclusion body myositis (sIBM)^{7, 9}. A definite diagnosis is conventionally confirmed by evidence of compound heterozygous or homozygous mutations in the *GNE* gene.

We report for the first time the clinical, histo-pathological, and genetic findings of all the patients with genetically confirmed *GNE* myopathy, diagnosed through the National Specialist Commissioning Team (NSCT) service for limb-girdle muscular dystrophies at Newcastle.

Methods

Clinical assessment

A total of 26 patients were recruited via the Newcastle MRC Neuromuscular Centre, Institute of Genetic Medicine, Newcastle upon Tyne. Genetic testing for GNE myopathy in the UK is only available through Newcastle as part of the NSCT. Comprehensive clinical histories and neurological examinations were completed during follow up clinic visits. All participants provided appropriate consent.

Further investigations included serum CK levels, respiratory function (using spirometry), ECG, and neurophysiological studies.

Magnetic resonance imaging (MRI) was performed in 7 patients. Axial and coronal planes of the pelvis and lower limbs were obtained using a conventional T1-weighted spin echo sequences. Muscle biopsies were performed in 20 patients, 2 patients had repeat biopsies. Muscle histology was assessed by standard procedures including H&E staining and were processed for immunohistochemistry (IHC) and multiplex western blot (WB)¹.

Sequence analysis

Genomic DNA was extracted from venous blood taken from patients and family members where available, by automated DNA extraction on the M48 BioRobot using the MagAttract DNA blood Mini M48 kit (Qiagen 951336) as part of the routine service performed by the Northern Region Genetics service molecular laboratory.

Direct sequencing for coding exons 1 to 13, GenBank accession (NM_001128227.2) of the *GNE* gene was carried out plus more than 10 nucleotides of 5' and 3' intronic sequence. Alamut-Mutation interpretation software (interactive biosoftware) was used to predict the pathogenicity of novel variants.

Results

Geographical and demographic characteristics

Genetic testing in Newcastle became available in September 2010 and a total of 87 full *GNE* gene screens have been performed since. 64% of the 87 referrals were from England, 14% were from Northern Ireland and 13% were from Scotland. The remaining referrals were from abroad. In total, 26 patients with *GNE* myopathy were identified, 12 females and 14 males from 23 kinships referred between 1987 and 2013. 10 of the 26 patients were from Scotland, 8 were from Northern Ireland and 7 from England. 1 patient was referred from the Republic of Ireland (figure 1).

Based on our data, the point prevalence of *GNE* myopathy in Britain (England, Scotland and Northern Ireland) is 0.04 per 100 000 population. The point prevalence for Scotland is 0.19 per 100,000 population, Northern Ireland 0.44 per 100,000 population and England 0.01 per 100,000 population. Of note the point prevalence of *GNE* myopathy in Japan is 0.3 per 100,000 population, one of the highest in the world. We accept that these figures need to be interpreted with caution in the absence of a more detailed population analysis and bearing in mind the challenges of disease ascertainment of *GNE* myopathy; however, it is worth noting that the estimated disease prevalence in Northern Ireland is close and possibly higher than in Japan.

Clinical features

The mean age of onset was 30 ± 9.238 years (range 10-44 years). 14 patients presented in the fourth decade of life with two patients presenting in their fifth decade. The earliest age of onset reported was around the age of 10 years (table 1).

Most patients presented with leg weakness (23/26). Three patients presented with calf muscle wasting, difficulties playing football and tripping respectively. Most of those presenting with weakness had distal weakness (21/23). 23/26 were found to have either unilateral (9/23) or bilateral (14/23) foot drop at the first clinical assessment. It is worth noting that all patients with unilateral foot drop progressed to developing bilateral foot drop. Quadriceps sparing was evident at presentation in 21/26 patients and was still a feature at the most recent clinical assessment in 17 of these patients.

Scapular winging was observed in 11/26 patients being asymmetric in 3 and symmetric in 8 patients and was noted at onset of disease in 4 patients.

Most patients remained ambulant (21/26) with 5/26 being wheelchair dependent. The non-ambulant group was older with a mean age of 57.2 ± 3.513 . 10 patients with a disease onset of 15 years or more retained the ability to walk. One of these however needed to use a

wheelchair outdoors. Involvement of upper limb muscles, both proximal and distal, was seen in the majority of patients (22/26) on subsequent assessments (table 2).

Serum CK was elevated in most patients (mean 447.9 ± 321.8 ; range 75-1400) but was normal in 5 patients. Neurophysiological data was available for 14/26 patients. Myopathic features on EMG were seen in 11/14. Of the 7 patients in whom we had detailed EMG reports, the myopathic features were most evident in the anterior compartment of the distal lower limb, correlating with the clinical pattern of distal muscle weakness. Neurogenic changes were reported in 3/14 patients.

Muscle pathology reports were available in 20 patients. All biopsies showed at least mild myopathic changes except in 2, which were reported as normal or showed neurogenic features respectively. Information on site of muscle sampling was available in 8 patients with the femoral quadriceps muscle being the most common site. In 3 patients biopsies were sampled from both the quadriceps and tibialis anterior muscles. Scattered cytoplasmic rimmed vacuoles/inclusions were identified in 5 patients only. There was evidence of inflammatory infiltrates in 3 biopsies. Muscle MRI of the lower limbs was carried out in 7 patients (figure 2). Most images exhibited varying degrees of symmetrical muscle atrophy with relative sparing of the quadriceps in all.

Mutation analysis

21 patients were compound heterozygotes and 5 were homozygotes (in the absence of known consanguinity) with different *GNE* mutations (table 1). A total of 14 missense and 2 frameshift mutations were identified. Two frameshift mutations (c.805delG, Asp269Metfs*11 and c.1313dupT, p.Ser439Lysfs*6) and 6 missense mutations were novel (p.Ile618Thr, p.Gly393Glu, p.Asp111Tyr, p.Leu281Met, p.Gly86Arg and p.Val362Gly). Of note, a previous pathogenic mutation (p.Val362Ala) was reported at the same position as our mutation p.Val362Gly10. Pathogenicity of the novel missense mutations was confirmed by parental testing showing segregation and/or *in silico* prediction tools (table 3). It is worth noting that 2 patients of Asian descent and a Northern English patient harboured the same heterozygous mutation (c.2179G>A, p.Val727Met).

Two previously reported mutations (c.1985C>T, p.Ala662Val and c.1225G>T, p.Asp409Tyr) were highly prevalent in the Scottish, Northern Irish and Northern English population. Both mutations were often found in the same patient in a compound heterozygous state. In 5 patients, mutation (p.Ala662Val) was found in a homozygous state. Notably, these mutations were responsible for 33/52 pathogenic alleles (63%) in patients harbouring 2 mutations for the entire cohort, and 33/40 pathogenic alleles (83%) in patients from the North of the UK (Northern England, Scotland and Northern Ireland). 90% (18/20) of patients from the North of the UK carried at least 1 of these mutations. We compared the clinical features of patients homozygous for p.Ala662Val (n=5) or compound heterozygous for p.Ala662Val and p.Asp409Tyr (n=10) with the remaining patients (n=11) and found no significant difference.

Discussion

GNE myopathy is an important diagnosis to consider in patients presenting with distal leg muscle weakness and elevated CK. This phenotype may be diagnostically challenging as it can mimic an inherited neuropathy or an alternative form of recessive distal myopathy like LGMD2B (Myoshi phenotype), caused by dysferlin mutations^{11, 12}. The sporadic form of inclusion body myositis shares important pathological features with GNE myopathy, namely the presence of inclusions on muscle biopsy, but should be reasonably distinguished from the inherited form, based on the later age of onset, the clear preservation of quadriceps muscles in GNE myopathy and evidence of inflammatory infiltrates in the majority of sporadic cases of inclusion body myositis^{9, 13}.

We describe a sizeable GNE myopathy cohort which exhibits similarities to other previously reported patients with regard to age of onset, quadriceps muscle sparing and the progressive nature of the disease^{14–17}. None of our patients developed respiratory insufficiency. The UK cohort is smaller than the previously described cohorts in Japan and Israel, and any conclusions are limited, but the clinical variability in both age of onset and progression appears to be greater in the UK. We also note some asymmetry of weakness (unilateral foot drop and scapular winging) at onset in several patients and slow disease progression. More than half of our patients with a disease duration of more than 15 years remained ambulant. Both quadriceps sparing and asymmetry of muscle involvement were noted on muscle MRI and correlated with clinical signs.

Rimmed vacuoles, thought to be the hallmark of the condition, were only confirmed in a small proportion of patients. This may be related to the site of the biopsies sampled, with the quadriceps muscle being most frequently sampled and the least affected clinically (figure 3). This, in addition to the distal and sometimes asymmetric presentation, may have led to a delay in diagnosis. In our cohort, the mean delay in diagnosis from symptom onset was 17.21 years $\pm$ 11.91 years (range 3–53 years). With the introduction of genetic testing in the UK in 2010, molecular confirmation became more achievable leading to shorter diagnostic delays.

Previous studies have indicated a possible association of homozygous kinase domain mutations in the context of early disease onset, and low level CK with a higher risk of respiratory failure¹⁸. None of our patients developed respiratory insufficiency. One patient was reported to have mild systolic dysfunction and further investigations are awaited to ascertain its significance. Interestingly, the Northern Irish patients harbouring the p.A662V mutation exhibited a particular gradient of weakness in the distal deep finger flexors with more involvement of the index finger compared to the little finger in both hands. To our knowledge, this is the first description of such selective muscle involvement in the distal upper limbs and seems to correlate with the genotype of the patient.

More than 60 mutations in the *GNE* gene have been associated with muscle pathology^{5, 19–21}. In our cohort, mutation analysis revealed a number of novel missense (p.Ile618Thr, p.Gly393Glu, p.Asp111Tyr, p.Leu281Met, p.Gly86Arg and p.Val362Gly) and frameshift variants (c.805delG, Asp269Metfs*11 and c.1313dupT, p.Ser439Lysfs*6) spanning the

length of the *GNE* gene with no suggestion of hot spots nor mutations in the allosteric domain.^{5, 10, 21–23.}

We have not identified any of the common mutations previously described in the Jewish and Japanese populations. Interestingly, we identified 2 very common mutations (c.1985C>T, p.Ala662Val and c.1225G>T, p.Asp409Tyr) in 18 out of the 20 patients diagnosed in Northern England, Scotland and Northern Ireland; with 5 homozygotes carrying the c.1985C>T, p.Ala662Val. 10 patients were compound heterozygotes for both mutations. The c.1225G>T, p.Asp409Tyr mutation had previously been reported in 5 individuals: 2 from the United States, 2 from Scotland and 1 from Ireland^{10, 21}. This is in keeping with the hypothesis that p.Asp409Tyr is a Northern British founder mutation. The c.1985C>T, p.Ala662Val mutation has previously been described in other populations of German, Irish, Jewish, American, Scottish, Japanese and more recently Chinese background^{5, 10, 16, 21, 23–25}. Therefore, this mutation may be generally very frequent or may have arisen several times in different populations. The predominance of these two mutations in the Northern British population is very striking and one should clearly consider a diagnostic strategy which may include early testing for the common *GNE* mutations in the UK and probably other parts of Europe.

GNE encodes for a bifunctional enzyme (uridine diphospho-N-acetylglucosamine (UDP-GlcNAc) 2-epimerase/N-acetyl-mannosamine (Man-NAc) kinase (GNE/MNK)) that catalyses the first two steps of sialic acid biosynthesis^{6, 8}. Sialic acid is the most abundant terminal monosaccharide on glycoconjugates in eukaryotes²⁶.

There are two distinct clinical entities associated with *GNE* mutations. The first is a metabolic disorder “sialuria” associated with excess sialic acid production. The other disorder is GNE myopathy. It is worth noting that the functional impact of mutants on enzymatic activity and the inhibitory feedback system of sialic acid biosynthesis are key in determining disease manifestation. Indeed, *GNE* mutations in sialuria have been shown to impair feedback inhibition of the UDP-GlcNAc 2-epimerase by CMP-sialic acid and may increase epimerase activity. This is in contrast to the reduced enzymatic function seen in GNE myopathy for both kinase and epimerase domains.

Complete loss of GNE expression is probably incompatible with life as evidenced by embryonic death seen with knock out inactivation of GNE in mice. In keeping with this hypothesis, all GNE patients identified so far carried a missense mutation at least on 1 of the mutated alleles, allowing for residual enzyme activity.

Remarkably in our cohort, 2 mutations seem to be very common: p.Ala662Val located in the kinase domain and p.Asp409Tyr positioned in the epimerase domain. Both these mutations have previously been reported and functionally characterised in vitro^{27, 28}. Mutation p.Asp409Tyr was shown to result in a 60% reduction of epimerase activity and an 80% reduction of kinase activity while p.Ala662Val mutation displayed only slight reduction in kinase and epimerase activities. In our patient cohort, patients homozygous for the Ala662Val had “milder” features with most presenting with unilateral foot drop and 4 out of 5 remaining ambulant after 3 to 19 years from disease onset. Whilst patients carrying one

heterozygous p.Asp409Tyr mutation were more likely to present with bilateral foot drop (7/10) and become non ambulant with 3 out of the 5 non ambulant patients in our cohort harbouring this heterozygous mutation.

Transgenic mice expressing a human *GNE* mutation (Japanese founder mutation) were crossed with heterozygous *GNE* knockout mice to obtain *Gne*^{-/-} transgenic hGNE D176V animals i.e. mice that express only mutant human *GNE* but no wild type mouse *GNE*²⁹. These mice show hyposialylation in muscle pathology after 42 weeks of age. Replenishing sialic acid metabolites was shown to prevent the disease phenotype in mice ³⁰. Based on these observations, phase 1 and phase 2 clinical trials using sialic acid or similar compounds have been initiated in the US and Japan Any preliminary observation from these studies would need to be confirmed in larger cohorts. The success of these therapeutic trials will rely on a robust genetic diagnosis of *GNE* myopathy, accurate estimation of disease prevalence and the collection of relevant natural history data and appropriate outcome measures from diverse patient cohorts.

Acknowledgements

The authors would like to thank the patients and clinicians who took part in this study. Diagnostic facilities at the Newcastle Muscle Centre are supported by the National Specialised Commissioning Team (NSCT) for rare neuromuscular disorders. The Institute of Genetic Medicine in Newcastle is part of the MRC Centre for Neuromuscular Diseases and the TREAT-NMD Alliance (www.treat-nmd.eu).

References

1. Pogue R, Anderson LV, Pyle A, et al. Strategy for mutation analysis in the autosomal recessive limb-girdle muscular dystrophies. *Neuromuscul Disord*. 2001; 11:80–87. [PubMed: 11166169]
2. Darin N, Kyllerman M, Wahlstrom J, Martinsson T, Oldfors A. Autosomal dominant myopathy with congenital joint contractures, ophthalmoplegia, and rimmed vacuoles. *Annals of neurology*. 1998; 44:242–248. [PubMed: 9708547]
3. Horowitz SH, Schmalbruch H. Autosomal dominant distal myopathy with desmin storage: a clinicopathologic and electrophysiologic study of a large kinship. *Muscle Nerve*. 1994; 17:151–160. [PubMed: 8114783]
4. Weihl CC, Pestronk A, Kimonis VE. Valosin-containing protein disease: inclusion body myopathy with Paget's disease of the bone and fronto-temporal dementia. *Neuromuscul Disord*. 2009; 19:308–315. [PubMed: 19380227]
5. Huizing M, Krasnewich DM. Hereditary inclusion body myopathy: a decade of progress. *Biochimica et biophysica acta*. 2009; 1792:881–887. [PubMed: 19596068]
6. Eisenberg I, Avidan N, Potikha T, et al. The UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase gene is mutated in recessive hereditary inclusion body myopathy. *Nature genetics*. 2001; 29:83–87. [PubMed: 11528398]
7. Argov Z, Mitrani-Rosenbaum S. Hereditary inclusion body myopathy and other rimmed vacuolar myopathies. *Handbook of clinical neurology*. 2007; 86:243–253. [PubMed: 18809004]
8. Argov Z, Mitrani-Rosenbaum S. The hereditary inclusion body myopathy enigma and its future therapy. *Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics*. 2008; 5:633–637. [PubMed: 19019317]
9. Krause S, Schlotter-Weigel B, Walter MC, et al. A novel homozygous missense mutation in the *GNE* gene of a patient with quadriceps-sparing hereditary inclusion body myopathy associated with muscle inflammation. *Neuromuscul Disord*. 2003; 13:830–834. [PubMed: 14678807]
10. Nishino I, Noguchi S, Murayama K, et al. Distal myopathy with rimmed vacuoles is allelic to hereditary inclusion body myopathy. *Neurology*. 2002; 59:1689–1693. [PubMed: 12473753]

11. Udd B. Distal muscular dystrophies. *Handbook of clinical neurology*. 2011; 101:239–262. [PubMed: 21496636]
12. Udd B. Distal myopathies--new genetic entities expand diagnostic challenge. *Neuromuscul Disord*. 2012; 22:5–12. [PubMed: 22197426]
13. Greenberg SA. Pathogenesis and therapy of inclusion body myositis. *Curr Opin Neurol*. 2012; 25:630–639. [PubMed: 22941263]
14. Argov Z, Eisenberg I, Grabov-Nardini G, et al. Hereditary inclusion body myopathy: the Middle Eastern genetic cluster. *Neurology*. 2003; 60:1519–1523. [PubMed: 12743242]
15. Sim JE, Park HJ, Shin HY, Nam TS, Kim SM, Choi YC. Clinical characteristics and molecular genetic analysis of Korean patients with GNE myopathy. *Yonsei medical journal*. 2013; 54:578–582. [PubMed: 23549799]
16. Lu X, Pu C, Huang X, Liu J, Mao Y. Distal myopathy with rimmed vacuoles: clinical and muscle morphological characteristics and spectrum of GNE gene mutations in 53 Chinese patients. *Neurological research*. 2011; 33:1025–1031. [PubMed: 22196754]
17. Khademian H, Mehravar E, Urtizberea J, et al. Prevalence of GNE p.M712T and hereditary inclusion body myopathy (HIBM) in Sangesar population of Northern Iran. *Clinical genetics*. 2012
18. Mori-Yoshimura M, Oya Y, Hayashi YK, Noguchi S, Nishino I, Murata M. Respiratory dysfunction in patients severely affected by GNE myopathy (distal myopathy with rimmed vacuoles). *Neuromuscul Disord*. 2013; 23:84–88. [PubMed: 23127962]
19. No D, Valles-Ayoub Y, Carbajo R, et al. Novel GNE Mutations in Autosomal Recessive Hereditary Inclusion Body Myopathy Patients. *Genetic testing and molecular biomarkers*. 2013; 17:376–382. [PubMed: 23437777]
20. Cai H, Yabe I, Shirai S, et al. Novel GNE compound heterozygous mutations in a GNE myopathy patient. *Muscle Nerve*. 2013
21. Eisenberg I, Grabov-Nardini G, Hochner H, et al. Mutations spectrum of GNE in hereditary inclusion body myopathy sparing the quadriceps. *Human mutation*. 2003; 21:99. [PubMed: 12497639]
22. Tomimitsu H, Ishikawa K, Shimizu J, Ohkoshi N, Kanazawa I, Mizusawa H. Distal myopathy with rimmed vacuoles: novel mutations in the GNE gene. *Neurology*. 2002; 59:451–454. [PubMed: 12177386]
23. Saechao C, Valles-Ayoub Y, Esfandiarifard S, et al. Novel GNE mutations in hereditary inclusion body myopathy patients of non-Middle Eastern descent. *Genetic testing and molecular biomarkers*. 2010; 14:157–162. [PubMed: 20059379]
24. Tomimitsu H, Shimizu J, Ishikawa K, Ohkoshi N, Kanazawa I, Mizusawa H. Distal myopathy with rimmed vacuoles (DMRV): new GNE mutations and splice variant. *Neurology*. 2004; 62:1607–1610. [PubMed: 15136692]
25. Vasconcelos OM, Raju R, Dalakas MC. GNE mutations in an American family with quadriceps-sparing IBM and lack of mutations in s-IBM. *Neurology*. 2002; 59:1776–1779. [PubMed: 12473769]
26. Keppler OT, Hinderlich S, Langner J, Schwartz-Albiez R, Reutter W, Pawlita M. UDP-GlcNAc 2-epimerase: a regulator of cell surface sialylation. *Science*. 1999; 284:1372–1376. [PubMed: 10334995]
27. Sparks SE, Ciccone C, Lalor M, et al. Use of a cell-free system to determine UDP-N-acetylglucosamine 2-epimerase and N-acetylmannosamine kinase activities in human hereditary inclusion body myopathy. *Glycobiology*. 2005; 15:1102–1110. [PubMed: 15987957]
28. Penner J, Mantey LR, Elgavish S, et al. Influence of UDP-GlcNAc 2-epimerase/ManNAc kinase mutant proteins on hereditary inclusion body myopathy. *Biochemistry*. 2006; 45:2968–2977. [PubMed: 16503651]
29. Malicdan MC, Noguchi S, Nonaka I, Hayashi YK, Nishino I. A Gne knockout mouse expressing human V572L mutation develops features similar to distal myopathy with rimmed vacuoles or hereditary inclusion body myopathy. *Human molecular genetics*. 2007; 16:115–128. [PubMed: 17164266]

30. Malicdan MC, Noguchi S, Hayashi YK, Nonaka I, Nishino I. Prophylactic treatment with sialic acid metabolites precludes the development of the myopathic phenotype in the DMRV-hIBM mouse model. *Nat Med.* 2009; 15:690–695. [PubMed: 19448634]

Figure 1. Geographical distribution of GNE myopathy patients referred to Newcastle between 1987 and 2012

A total of 87 full GNE gene screens have been performed in Newcastle since September 2010. 64% of the 87 referrals were from England, 14% were from Northern Ireland and 13% were from Scotland. The remaining referrals were from abroad. The majority of genetically confirmed GNE myopathy patients were referred from the North of Britain (Scotland, Northern Ireland and Northern England) with the highest numbers seen in Northern Ireland and Scotland.

Figure 2. T1-weighted MR images of 6 GNE myopathy patients.

Evidence of quadriceps sparing in all patients with distal involvement of muscles in the anterior and posterior compartments. (A) **Patient 15.** Severe atrophy of both *glutei maximi* muscles (*). Left *peroneus longus* seems relatively spared in the left lower leg more than right (arrow). (B) **Patient 10.** Asymmetrical atrophy of *rectii femoris* muscles (arrows). (C) **Patient 16.** Early involvement of *glutei minimi* (arrows) with sparing of *glutei maximi* muscles. (D) **Patient 19.** Bilateral atrophy of *iliopsoas*, *pectineus*, *adductor brevis* and *longus* muscles (arrows). (E) **Patient 9.** Early atrophy of *rectus femorii* and *vastus intermedius* muscles (arrows). (F) **Patient 5.** Atrophy of tensor fascia lata muscles bilaterally (arrows).

Figure 3. Evidence of myopathic features in tibialis anterior but not in quadriceps femoris. H&E stained sections from patient 2. A. Quadriceps femoris muscle $\times 100$: normal appearance. B. Tibialis anterior muscle $\times 200$: occasional necrotic fibres, fibre splitting, atrophic fibre, internal nuclei

Table 1
Clinical features and GNE genotypes of patients with genetically confirmed GNE-myopathy.

Patient	Sex	Geographical origin	Age	Age at onset	Mode of onset	Foot drop at onset	Quadriceps sparing	Other clinical features	Amputation at last assessment	CK	Allele 1	Allele 2
1	F	Scotland	64	10	R foot drop	Y-U	Y	SW & mild lower facial weakness	N	75	c.1985C>T, p.Ala662Val	c.1985C>T, p.Ala662Val
2	M	Scotland	56	37	Distal & proximal weakness	Y-U	Y	ASW	Y	389-533	c.1985C>T, p.Ala662Val	c.1985C>T, p.Ala662Val
3	F	Scotland	39	mid 20s	Foot drop	Y-B	Y**	SW #	Y†	417	c.1225G>T, p.Asp409Tyr	c.1985C>T, p.Ala662Val
4	M	Scotland	50	30	L foot drop	Y-U	Y	ASW & lower facial weakness	Y	163	c.691A>T, p.Ile231Phe	c.1085T>G, p.Val362Gly
5	F	Scotland	27	18	Distal & proximal weakness	Y-B	Y		Y	328	c.1985C>T, p.Ala662Val	c.740T>C, p.Val247Ala
6	M	Scotland	55	~30	Foot drop	Y-B	Y	Facial weakness & SW# & finger flexion & extension weakness	Y	1047	c.1225G>T, p.Asp409Tyr	c.1985C>T, p.Ala662Val
7	M	Scotland	49	37	L foot drop	Y-U	Y	Finger extensor weakness	Y	231	c.1225G>T, p.Asp409Tyr	c.841C>A, p.Leu281Met
8	F	Scotland	44	36	Distal & proximal weakness	Y-U	Y**	Facial weakness & SW	Y	288-456	c.1985C>T, p.Ala662Val	c.1985C>T, p.Ala662Val
9	F	Scotland	39	14	Foot drop	Y-B	Y		Y†	“normal”	c.1225G>T, p.Asp409Tyr	c.1985C>T, p.Ala662Val
10	M	Scotland	49	39	Foot drop	Y-U	Y	Finger extensor weakness & calf hypertrophy & systolic dysfunction	Y	359	c.1985C>T, p.Ala662Val	c.1985C>T, p.Ala662Val
11	F	N Ireland	34	31	Bilateral foot drop (after pregnancy)	Y-B	NS		Y	166	c.1985C>T, p.Ala662Val	c.1985C>T, p.Ala662Val
12*	M	N Ireland	57	35	Calf muscle wasting	NS	NS	SW & finger flexion weakness	N	NS	c.1985C>T, p.Ala662Val	c.1985C>T, p.Ala662Val
13*	M	N Ireland	59	27	Bilateral foot drop	Y-B	N		N	614	c.1225G>T, p.Asp409Tyr	c.1985C>T, p.Ala662Val
14*	F	N Ireland	62	30	Bilateral foot drop	Y-B	Y	Finger flexion weakness	N	340	c.1225G>T, p.Asp409Tyr	c.1985C>T, p.Ala662Val
15*	M	N Ireland	53	20s	Difficulties playing football	NS	Y	SW & finger flexion weakness	Y	140-1400	c.1225G>T, p.Asp409Tyr	c.1985C>T, p.Ala662Val
16	M	N Ireland/India	48	44	Weak legs	Y-U	NS		Y	700-1200	c.2179G>A, p.Val727Met	c.1313dupT, p.Ser439Lysfs*6
17	F	N Ireland	61	39	Severe back & feet pain with unilateral foot drop	Y-U	Y		Y‡	NS	c.1225G>T, p.Asp409Tyr	c.1985C>T, p.Ala662Val
18	F	N Ireland	55	35	Unilateral foot drop	Y-U	Y	Finger flexion	Y	288	c.691A>T, p.Ile231Phe	c.805del G, Asp269Metfs*11
19	M	ROI	25	22	Leg weakness	Y-B	Y	Facial weakness & ASW	Y	441	c.1853T>C, p.Ile618Thr	c.331G>T, p.Asp111Tyr
20	M	N England	51	unclear	Bilateral foot drop	Y-B	Y		Y	NS	c.1225G>T, p.Asp409Tyr	c.2179G>A, p.Val727Met
21	F	N England	50	34	Bilateral foot drop	Y-B	Y		Y	“marginally raised”	c.1225G>T, p.Asp409Tyr	c.1985C>T, p.Ala662Val

Patient	Sex	Geographical origin	Age	Age at onset	Mode of onset	Foot drop at onset	Quadriceps sparing	Other clinical features	Amputation at last assessment	CK	Allele 1	Allele 2
22	M	N England (ROI)	42	30s	Unilateral wasting & limping	Y-B	Y**	SW#	Y	170	c.1225G>T, p.Asp409Tyr	c.1985C>T, p.Ala662Val
23	F	S England	46	30s	Bilateral foot drop	Y-B	Y		Y	283	c.479G>A, p.Arg160Gln	c.922C>T, Arg308Cys
24*	M	S England	44	20	Tripping	NS	NS		N	400	c.830G>A, p.Arg277Gln	c.1178G>A, p.Gly393Glu
25*	M	S England	42	early 20s	Distal leg weakness	Y-B	Y**	SW#	Y	309	c.830G>A, p.Arg277Gln	c.1178G>A, p.Gly393Glu
26	F	S England/Pakistan	40	32	Bilateral foot drop & proximal upper limb weakness	Y-B	Y		Y	485	c.2179G>A, p.Val727Met	c.256G>A, p.Gly86Arg

Highlighted in bold are the two common mutations (c.1985C>T, p.Ala662Val and c.1225G>T, p.Asp409Tyr) of the *GNE* gene. GenBank accession number (NM_001128227.2). Nucleotide numbering reflects cDNA numbering with +1 corresponding to the A of the ATG translation initiation codon in the reference sequence.

[‡]Denotes siblings.

^{*}Quadriceps power not commented on at most recent assessment.

[‡]Using wheelchair to mobilise outdoors.

[§]Last clinical assessment was in 2008.

B, bilateral; CK, creatine kinase; NS, not stated; ROI, Republic of Ireland; U, unilateral.

Table 2
Summary table of clinical features in patients with genetically confirmed GNE-myopathy.

Clinical feature	No. of affected patients
Unilateral foot drop at onset	9/26
Bilateral foot drop at onset	14/26
Quadriceps spared at follow up	17/26
Asymmetrical scapular winging	3/26
Bilateral scapular winging	8/26
Facial weakness	5/26
Finger flexion weakness	5/26
Finger extension weakness	3/26
Ambulant	21/26
Rimmed vacuoles	4/19

Frequency of clinical signs and symptoms relative to the total number of patients assessed.

Table 3
Properties of GNE mutations identified in the British cohort.

Mutation (NM_001128227.2)	Old nomenclature (NM 005476.3)	Geographical origin	Zygosity	Exon	Domain	Prediction (SIFT/Mutation Taster)
c.256G>A, p.Gly86Arg	Novel	1 Southern England/Pakistan	1 CHz pt	3	Epimerase	Disease causing
c.331G>T, p.Asp111Tyr	Novel	1 ROI	1 CHz pt	4	Epimerase	Disease causing
c.479G>A, p.Arg160Gln	c.386G>A, p.Arg129Gln	1 Southern England	1 CHz pt	4	Epimerase	Disease causing
c.691A>T, p.Ile231Phe	c.649A>T, p.Ile200Phe	1 Scotland, 1 Northern Ireland	2 CHz pts	4	Epimerase	Disease causing
c.740T>C, p.Val247Ala	c.647T>C, p.Val216Ala	1 Scotland	1 CHz pt	5	Epimerase	Disease causing
c.805del G, Asp269Metfs*11	Novel	1 Northern Ireland	1 CHz pt	5	Epimerase	Frameshift/disease causing
c.830G>A, p.Arg277Gln	c.737G>A, p.Arg246Gln	2 Southern England	2 CHz pts (sib pair)	5	Epimerase	Inconclusive
c.841C>A, p.Leu281Met	Novel	1 Scotland	1 CHz pt	5	Epimerase	Disease causing
c.922C>T, Arg308Cys	c.829C>T, p.Arg277Cys	1 Southern England	1 CHz pt	6	Epimerase	Disease causing
c.1085 T>G, p.Val362Gly	Novel	1 Scotland	1 CHz pt	7	Epimerase	Disease causing
c.1178G>A, p.Gly393Glu	Novel	2 Southern England	2 CHz pts (sib pair)	8	Kinase	Disease causing
c.1225G>T, p.Asp409Tyr	c.1132G>T, p.Asp378Tyr	3 Northern England, 5 Northern Ireland, 4 Scotland	12 CHz pts (2 sib pairs)	8	Kinase	Disease causing
c.1313dupT, p.Ser439Lysfs*6	Novel	1 Northern Ireland/India	1 CHz pt	8	Kinase	Frameshift/disease causing
c.1853T>C, p.Ile618Thr	Novel	1 ROI	1 CHz pt	11	Kinase	Disease causing
c.1985C>T, p.Ala662Val	c.1892C>T, p.Ala631Val	2 Northern England, 6 Northern Ireland, 8 Scotland	5 Homoz pts, 11 CHz pts (2 sib pairs)	12	Kinase	Disease causing
c.2179G>A, p.Val727Met	c.2187G>A, p.Val696Met	2 Asia, 1 Northern England	3 CHz pts	13	Kinase	Disease causing

Previously reported mutations have been annotated using the old nomenclature (GenBank accession number NM 005476.3) and new nomenclature (NM_001128227.2). The old *GNE* sequence differs by 93 nucleotides from current sequence. The old sequence had exon 1 as non-coding and had an initiation codon (ATG) half way through the current exon 2. Variants named using the old sequence need to have 93 added on to the nucleotide position to find nomenclature according to current sequence.

CHz pt, compound heterozygous patient; Homoz pt, homozygous patient; ROI, Republic of Ireland.